Janux Therapeutics Q2 net loss narrows to $22.0 million from $33.9 million
Janux Therapeutics reported results for the three months ended June 30, 2026, with a net loss of $22.0 million, down from $33.9 million a year earlier. The company also recorded $10.3 million of collaboration revenue, compared with none in the same quarter of 2025, and ended the quarter with $970.9 million in cash, cash equivalents and short-term investments.
Key points
- Net loss per share was $0.35 for the quarter, compared with $0.55 in the second quarter of 2025.
- Collaboration revenue was $10.3 million in the quarter, versus no collaboration revenue in the prior-year quarter.
- Research and development expenses fell to $31.0 million from $34.7 million, while general and administrative expenses rose to $11.0 million from $10.5 million.
- Cash and short-term investments were $970.9 million at June 30, 2026, up from $966.6 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.